Kymera Therapeutics, Inc. (KYMR)
NASDAQ$34.37+0.92 (2.75%)
Market Cap
$2.17B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
406 of 924
Rank in Industry
237 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
KYMR Insider Trading Activity
KYMR Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $46 | 1 | 6 |
Sells | $27,253,780 | 17 | 94 |
Related Transactions
| BAKER BROS. ADVISORS LP | director | 1 | $46 | 0 | $0 | $46 |
| Chadwick Jeremy G | Chief Operating Officer | 0 | $0 | 2 | $132,218 | $-132,218 |
| Chiniara Ellen | Chief Legal Officer | 0 | $0 | 2 | $198,884 | $-198,884 |
| Jacobs Bruce N. | Chief Financial Officer | 0 | $0 | 1 | $214,219 | $-214,219 |
| Albers Jeffrey W. | director | 0 | $0 | 1 | $245,509 | $-245,509 |
| Horobin Joanna | director | 0 | $0 | 1 | $280,400 | $-280,400 |
| Esposito Pamela | director | 0 | $0 | 2 | $774,266 | $-774,266 |
| Gollob Jared | Chief Medical Officer | 0 | $0 | 3 | $1.98M | $-1.98M |
| Atlas Venture Fund X, L.P. | 10 percent owner | 0 | $0 | 1 | $5.88M | $-5.88M |
| Booth Bruce | director | 0 | $0 | 6 | $29.31M | $-29.31M |
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat …
Insider Activity of Kymera Therapeutics, Inc.
Over the last 12 months, insiders at Kymera Therapeutics, Inc. have bought $46 and sold $27.25M worth of Kymera Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Kymera Therapeutics, Inc. have bought $18.82M and sold $54.57M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP (director) — $46.
The last purchase of 1 shares for transaction amount of $46 was made by BAKER BROS. ADVISORS LP (director) on 2024‑08‑20.
List of Insider Buy and Sell Transactions, Kymera Therapeutics, Inc.
| 2025-03-03 | Sale | Jacobs Bruce N. | Chief Financial Officer | 7,035 0.011% | $30.45 | $214,219 | +9.06% | |
| 2025-03-03 | Sale | Gollob Jared | Chief Medical Officer | 5,740 0.009% | $30.45 | $174,786 | +9.06% | |
| 2025-03-03 | Sale | Chiniara Ellen | Chief Legal Officer | 2,241 0.0035% | $30.45 | $68,239 | +9.06% | |
| 2025-03-03 | Sale | Chadwick Jeremy G | Chief Operating Officer | 1,383 0.0022% | $30.45 | $42,113 | +9.06% | |
| 2025-01-06 | Sale | Chiniara Ellen | Chief Legal Officer | 3,129 0.005% | $41.75 | $130,645 | -6.24% | |
| 2024-12-02 | Sale | Esposito Pamela | director | 2,500 0.0039% | $49.00 | $122,500 | -17.27% | |
| 2024-09-17 | Sale | Esposito Pamela | director | 13,500 0.0216% | $48.28 | $651,766 | -8.96% | |
| 2024-08-26 | Sale | Albers Jeffrey W. | director | 5,000 0.0077% | $49.10 | $245,509 | -12.21% | |
| 2024-08-20 | BAKER BROS. ADVISORS LP | director | 1 <0.0001% | $46.41 | $46 | -5.24% | ||
| 2024-07-16 | Sale | Gollob Jared | Chief Medical Officer | 23,145 0.0578% | $45.81 | $1.06M | -9.98% | |
| 2024-07-15 | Sale | Gollob Jared | Chief Medical Officer | 16,455 0.0405% | $45.15 | $742,925 | -2.94% | |
| 2024-07-09 | Sale | Booth Bruce | director | 453,960 0.9459% | $38.21 | $17.35M | +10.66% | |
| 2024-06-13 | Sale | Booth Bruce | director | 10,200 0.0168% | $34.98 | $356,796 | +23.62% | |
| 2024-06-12 | Sale | Booth Bruce | director | 16,740 0.028% | $35.45 | $593,378 | +24.57% | |
| 2024-06-07 | Sale | Horobin Joanna | director | 8,500 0.0139% | $32.99 | $280,400 | +30.64% | |
| 2024-05-23 | Sale | Chadwick Jeremy G | Chief Operating Officer | 2,575 0.0043% | $34.99 | $90,105 | +24.66% | |
| 2024-03-15 | Sale | Booth Bruce | director | 71,764 0.1171% | $40.46 | $2.9M | +0.18% | |
| 2024-03-14 | Sale | Booth Bruce | director | 55,779 0.0861% | $39.98 | $2.23M | +2.89% | |
| 2024-03-13 | Sale | Booth Bruce | director | 139,255 0.2271% | $42.23 | $5.88M | -3.95% | |
| 2024-03-13 | Sale | Atlas Venture Fund X, L.P. | 10 percent owner | 139,255 0.2271% | $42.23 | $5.88M | -3.95% |
Total: 115
*Gray background shows transactions not older than one year
Insider Historical Profitability
37.23%
| BAKER BROS. ADVISORS LP | director | 5516986 8.495% | $184.54M | 1 | 0 | |
| BVF PARTNERS L P/IL | director | 2656191 4.09% | $88.85M | 8 | 0 | +27.91% |
| LAMPERT MARK N | 257754 0.3969% | $8.62M | 4 | 0 | +55.87% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$66,492,695 | 135 | 27.65% | $2.03B | |
$1,376,668 | 53 | 18.46% | $2.27B | |
$224,267,561 | 40 | 26.78% | $2.18B | |
$62,927,079 | 29 | 14.02% | $2.25B | |
$150,253,463 | 26 | -52.83% | $2.22B |
KYMR Institutional Investors: Active Positions
| Increased Positions | 96 | +47.76% | 7M | +9.67% |
| Decreased Positions | 87 | -43.28% | 4M | -5.19% |
| New Positions | 34 | New | 3M | New |
| Sold Out Positions | 28 | Sold Out | 1M | Sold Out |
| Total Postitions | 210 | +4.48% | 72M | +4.48% |
KYMR Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Price T Rowe Associates Inc /Md/ | $215,385.00 | 10.57% | 6.87M | +224,859 | +3.38% | 2024-12-31 |
| Baker Bros. Advisors Lp | $187,972.00 | 9.23% | 6M | 0 | 0% | 2024-12-31 |
| Wellington Management Group Llp | $166,385.00 | 8.16% | 5.31M | +688,967 | +14.92% | 2024-12-31 |
| Bvf Inc/Il | $161,822.00 | 7.94% | 5.16M | 0 | 0% | 2024-12-31 |
| Avoro Capital Advisors Llc | $161,453.00 | 7.92% | 5.15M | +650,000 | +14.44% | 2024-12-31 |
| Atlas Venture Life Science Advisors, Llc | $153,504.00 | 7.53% | 4.9M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $153,217.00 | 7.52% | 4.89M | +133,546 | +2.81% | 2024-12-31 |
| Fmr Llc | $151,434.00 | 7.43% | 4.83M | -278,718 | -5.46% | 2024-12-31 |
| Blackrock, Inc. | $136,570.00 | 6.7% | 4.36M | +144,654 | +3.44% | 2024-12-31 |
| Siren, L.L.C. | $93,101.00 | 4.57% | 2.97M | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.